SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Innoviva Reports Third-Quarter 2026 Financial Results

Innoviva reported its third-quarter 2026 financial results.

INVA

Innoviva, Inc. (NASDAQ:INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets…

Related stories